Gene Profiling in Clinical Oncology - Slide 3 - O. Gautschi - Do we know how to chose the best maintenance treatment?

  • 326 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
326
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Do we know how to choose the
    best maintenance treatment?
    oliver.gautschi@onkologie.ch
  • 2. Firstline therapy (metastatic disease)
    Continuation maintenance
    Switch maintenance
    Secondline therapy (at progression)
    2
    Definitions
  • 3. Delay tumor progression
    Prolong survival
    Optimal tolerance
    No cumulative toxicity
    Maintain life quality
    3
    Aims and Expectations
  • 4. Meta-analysis: PFS Soon JCO 2009
  • 5. Meta-analysis: OS Soon JCO 2009
  • 6. Continuation chemotherapy
    is not standard-of-careBelani ASCO 2010
  • 7. Continuation of Bevacizumab ?Sandler NEJM 2006; Reck JCO 2009
    E4599: cont. 53%
    AVAiL : cont. 41-42%
  • 8. Switch to Pemetrexed: JMENCiuleanu ASCO 2008, Lancet Oncol 2010
    Gem / Platin
    Pac / Platin
    Doc / Platin
    No PD
    PS 0,1
  • 9. JMEN: HistologyBelani ASCO 2009, Ciuleanu Lancet 2009
  • 10. JMEN : initial ResponseCiuleanu, Lancet 2009
    OS for non-squamous:
    HR
    CR/PR
    0.81
    0.61
    SD
    1.2
    1.0
    0.8
    0.6
    0.4
    Favours pemetrexed
    Favours placebo
  • 11. JMEN : ToxicityCiuleanu, Lancet 2009
    Relevant grade 2 toxicities
    Fatigue
    Nausea 20 %
    Anorexie
  • 12. Switch to Erlotinib: SATURNCappuzzo ASCO 2009 / Lancet Oncol 2010
  • 13. SATURN: OSCappuzzo, Lancet Oncol 2010
  • 14. SATURN: SubgroupsCappuzzo, Lancet Oncol 2010
  • 15. Response to Firstline TherapyCappuzzo, Lancet Oncol 2010
  • 16. SATURN: EGFR MutationBrugger, ASCO 2009
    EGFR mutation
    EGFR wild type
    HR=0.10 (0.04–0.25)
    HR=0.78 (0.63–0.96)
    1.0
    0.8
    0.6
    0.4
    0.2
    0
    1.0
    0.8
    0.6
    0.4
    0.2
    0
    Log-rank p<0.0001
    Log-rank p=0.0185
    PFS probability
    0 8 16 24 32 40 48 56 64 72 80 88 96
    0 8 16 24 32 40 48 56 64 72 80 88 96
    Time (weeks)
    Time (weeks)
  • 17.
  • 18. What did we learn from these
    registration trials ?
    Maintainance therapy is an approved option
    Histology is predictive for pemetrexed
    EGFR mutations are predictive for erlotinib
    but it is still not proven if maintenance offers a true survival advantage over secondline therapy with the same drug given at the right time
  • 19. Ongoing Phase III Trials
  • 20. Large Cell
    Small Cell
    Squamous
    Adeno
    M. Gugger, Bern University
  • 21. Predictive Markers for ChemotherapyGandara, Curr Opin Oncol 2010
    Histology is a predictive factor for
    pemetrexed, gemcitabine and bevacizumab.
    Are molecular markers better ? Candidates:
    TTF1, ERCC1, TS, BRCA1, gene signatures
  • 22.
  • 23. TS and Drug ResistanceOzasa, Cancer Sci 2010
    23
  • 24. SAKK19/09 (BIOPRO)Multicenter phase II trial
  • 25. EGFR T790M Kobayashi, NEJM 2005
    25
  • 26.
  • 27.
  • 28. Case 1: EGFR mutation
    15 MAR 2010
    18 MAR 2011
    Erlotinib
    28
  • 29. EGFR-TKI and Line of TherapyMok ESMO 2010, Rosell NEJM 2009
  • 30. Case 2: ALK Translocation
    Crizotinib
    19 FEB 2011
    17 MAR 2011
  • 31. ALK-FISHJ. Diebold, Pathology Luzern
    HE: Adenocarcinoma with signet ring cells
    ALK FISH (break apart probe): positive (patient)
    IHC: TTF1 +
    ALK FISH (break apart probe): negative control
  • 32. ALK Inhibitor Crizotinib Kwak, NEJM 2010
    pretreated = 94%
  • 33. ETOP
    LUNGSCAPE
  • 34. Sequential TestingHorn, JCO 2009
  • 35. Parallel TestingKim AACR 2010+11
  • 36. Circulating DNAJCO 2004/Cancer Lett 2007
    mKRAS
    wtKRAS
  • 37. Mok, IPASS 2010
  • 38. Emerging markers: FGFR Weiss, Science Translat Med 2010
  • 39. Perspectives Gandara 2010
  • 40. Enroll patients in clinical trials
    If not possible, consider switch maintenance if SD, good PS or symptomatic
    Pemetrexed if non-SQ and not pretreated
    Erlotinib if SQ or previous pemetrexed or oral drug preferred
    Test for EGFR and ALK
    Recommendations
  • 41. Disclosure Slide
    Chair of investigator-initiated clinical trials supported by Roche, Eli Lilly, AMGEN, Bayer
    Advisory role for AstraZeneca
    No stocks
    No employment